The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...

In year two of the trial, Elevidys demonstrated statistically significant and clinically improvements across three key ...

Roche has reported positive topline outcomes from the second year of the multinational Phase III EMBARK trial of Elevidys ...

Roche on Monday revealed positive results from the EMBARK trial, showing that its gene therapy Elevidys has sustained ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Swiss pharma giant Roche today announced positive top-line results from year two of the EMBARK trial, a global, randomized, ...

Top-line Phase 3 trial data show ambulatory boys with Duchenne continued with motor improvements two years after a single ...

Roche and Sarepta Therapeutics have shared positive top-line results from a late-stage study of Elevidys (delandistrogene ...

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

Roche has reported positive results from the second year of the EMBARK Phase III trial of Elevidys (delandistrogene moxeparvovec), the first approv ...

The firm will share new overall survival data from the INAVO120 trial with regulators to support the breast cancer drug's approval.